Immuron stock falls 6.77 percent as FY26 sales rise 5.9 percent

Published on 09/23/2026 at 22:31 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Immuron stock posted FY26 revenue of AUD 7,713,601, up 5.9 percent from FY25. Cash reached AUD 9,017,814 while the company expanded PROIBS into the U.S. market.

Immuron stock, biotechnology, PROIBS, distribution agreement, Nasdaq, Illustration mit AI erstellt.

Immuron stock (ISIN US45254U1016) was trading at USD 1.17 on Nasdaq on September 23, 2026, down 6.77 percent from USD 1.25. The move follows a commercial expansion story that produced record FY26 revenue but still left the biotechnology company loss-making.

PROIBS reaches U.S. distribution

Immuron executed an exclusive U.S. distribution agreement for PROIBS with Calmino group AB on September 4, 2026. The product had already launched in Australia during fiscal year 2026, extending Immuron's digestive-health portfolio beyond Travelan.

GlobeNewswire reported that the agreement covers the United States, although the release did not provide a purchase commitment or financial terms. For investors, that makes the deal a route to a larger market rather than a booked revenue event.

FY26 sales reach AUD 7.7 million

According to Stock Titan, Immuron reported preliminary FY26 revenue of AUD 7,713,601 for the year ended June 30, 2026, compared with AUD 7,287,002 in FY25. That represents a 5.9 percent increase and gives the distribution agreement a larger commercial base than the company had one year earlier.

FY26 net loss narrowed to AUD 3,838,699 from AUD 5,215,987, an improvement of AUD 1,377,288. Cash rose to AUD 9,017,814 from AUD 2,830,526, while operating cash flow improved to negative AUD 3,259,720 from negative AUD 6,136,949.

Nasdaq price turns lower

Immuron's Nasdaq quote stood at USD 1.17 on September 23, 2026, after a USD 0.09 decline from the prior session. The current market capitalization was USD 7,541,475, while the 52-week range was USD 0.68 to USD 2.39.